Skip to content

Pharmacogenomics of Drug Safety in Multiple Sclerosis

Multiple Sclerosis

To investigate whether genotypic differences can be identified between MS patients developing 'liver injury' (defined as ALT levels five times the upper normal limit and above) compared to those not developing liver injury after exposure to beta-interferon for MS.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria: Cases and controls must have

* definite MS (Poser or McDonald criteria)
* relapsing-remitting or secondary-progressive disease course
* Prescribed a beta-interferon as their immunomodulatory drug for MS

Exclusion Criteria:

* primary-progressive MS
* an elevated liver test result within 6 months of starting beta-interferon treatment
* presence of a co-morbidity that is a known risk-factor for liver injury

Study Location

London Health Sciences Centre MS clinic
London Health Sciences Centre MS clinic
London, Ontario
Canada

Contact Study Team

Dalhousie MS Research Unit
Dalhousie MS Research Unit
Halifax, Nova Scotia
Canada

Contact Study Team

MS Clinic UBC Hospital
MS Clinic UBC Hospital
Vancouver, British Columbia
Canada

Contact Study Team

Hôpital Notre-Dame MS clinic
Hôpital Notre-Dame MS clinic
Montréal, Quebec
Canada

Contact Study Team

Winnipeg Health Sciences Centre
Winnipeg Health Sciences Centre
Winnipeg, Manitoba
Canada

Contact Study Team

Study Sponsored By
University of British Columbia
Participants Required
More Information
Study ID: NCT01118130